MedPath

A study to observe if probiotics supplementation is helpful in atopic dermatitis children

Phase 3
Recruiting
Conditions
Patients of atopic dermatitis but who have chronic illness and are immunosuppressive are not recruited in the study.
Registration Number
CTRI/2017/08/009236
Lead Sponsor
PGIMER Chandigarh
Brief Summary

Recruitment of the patients have already been started for the study with proper written consent and it is under process.

Detailed Description

Not available

Recruitment & Eligibility

Status
Open to Recruitment
Sex
All
Target Recruitment
114
Inclusion Criteria
  • Children with atopic dermatitis diagnosed according to Hanifin and Rajka between aged 6 months to 12 years.
  • All children in the above mentioned age group with be eligible irrespective of the disease severity.
Exclusion Criteria
  • Immunocompromised chilren 2.
  • Children with severe hepatic, renal or other systemic disease 3.
  • <6 months and >12 years of age.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
1. The mean difference in SCORAD in children with AD treated with conventional treatment plus probiotic supplementation versus conventional treatment alone at 0,12 and 24 weeks.0,12 and 24 weeks
2. Mean difference in the number of days of treatment required to achieve 90% reduction in SCORAD in children with AD treated with conventional treatment plus probiotic supplementation versus conventional treatment alone.0,12 and 24 weeks
3. Number of children with AD who relapse after stoppage of treatment at 24 weeks0,12 and 24 weeks
Secondary Outcome Measures
NameTimeMethod
1. To compare the IL-17 level in treatment vs control group at baseline and at 12 weeks2. To compare the CDLQI and IDQOL at baseline and at 12 and 24 weeks

Trial Locations

Locations (1)

PGIMER

🇮🇳

Chandigarh, CHANDIGARH, India

PGIMER
🇮🇳Chandigarh, CHANDIGARH, India
Richa Sharma
Principal investigator
8284808032
reechasharma99@gmail.com

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.